New COVID Variant 2026: BA.3.2 Spreading Across the US
Health officials are closely monitoring a new variant of COVID-19, designated BA.3.2, as it spreads across the United States and internationally. As of February 11, 2026, at least 23 countries have reported cases of this emerging strain, according to a recent study published by the Centers for Disease Control and Prevention (CDC).
The BA.3.2 variant is notable for its significant genetic divergence. It boasts approximately 70 to 75 changes in the gene sequence of its spike protein – the crucial structure on the virus’s surface that facilitates entry into human cells. This substantial mutation count is raising concerns among public health experts.
Detection and Spread
The CDC’s Traveler-Based Genomic Surveillance program first detected BA.3.2 in the U.S. in June 2025, originating from a traveler arriving from the Netherlands. Since then, the variant has been identified in a variety of samples:
- Nasal swabs from four U.S. travelers
- Clinical samples from five patients
- Three airplane wastewater samples
- 132 wastewater surveillance samples from 25 states
Between November 2025 and January 2026, weekly detections of BA.3.2 surged to around 30% of identified cases in Denmark, Germany, and the Netherlands, indicating a rapid increase in its prevalence in those regions.
Immune Escape and Potential Impact
A key characteristic of the BA.3.2 variant is its demonstrated “immune escape characteristics.” The CDC reports that the mutations present may allow the virus to partially evade immunity gained from prior vaccination or infection. While this doesn’t necessarily mean more severe illness, it does suggest a higher likelihood of infection, even in individuals with some level of protection. The CDC provides detailed information on variants and their potential impact.
Researchers emphasize that BA.3.2 represents a distinct lineage of SARS-CoV-2, genetically different from the JN.1 lineages (including LP.8.1 and XFG) that have been circulating since January 2024.
Ongoing Surveillance is Crucial
The researchers acknowledge that the actual prevalence of BA.3.2 may be higher than current data indicates, as many countries lack comprehensive genomic detection and surveillance capabilities. Furthermore, the emergence of two sublineages (BA.3.2.1 and BA.3.2.2) highlights the ongoing evolution of the virus.
The CDC stresses the importance of continued genomic surveillance to monitor the virus’s evolution and assess its potential impact on public health. Understanding how BA.3.2 behaves and spreads is vital for informing public health strategies and protecting vulnerable populations. For more information on COVID-19 and preventative measures, visit the World Health Organization website.
